Results

Total Results: 2,078 records

Showing results for "drugs".

21. Developing Evidence-Based Research Priorities for Off-Label Drug Use | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/off-label-use-research-priorities/research
    June 29, 2009 - years (based from 12/31/06) were coded as 1.0, drugs approved between 4-13 years as 0.5, and drugs approved … drugs are consistent across the lists. … Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals … The Drug Safety index value is coded as 1 for drugs with a black box warning, 0.5 for drugs that had … The Market Entry index value is coded as 1 for drugs that entered within the past 3 years, 0.5 for drugs

22. Comparative Effectiveness of Dietary Supplement Versus No Dietary Supplement Use in Adults Taking Cardiovascular Drugs | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/dietary-supplements/research-protocol
    December 21, 2010 - dietary supplements (when compared to cardiovascular drugs alone or cardiovascular drugs and a different … Classes of commonly used cardiovascular drugs to be considered (excluding drugs used exclusively for … Analytic Framework for Dietary Supplement Use in Adults Taking Cardiovascular Drugs. … Drugs Aging 2009;26(Suppl 1):41-51. Garner JB. … Drugs 2009;69:1777-98. Miller KL, Liebowitz RS, Newby LK.

23. Chicago-Area DEcIDE Center (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/off-label-use-research-priorities_research.pdf
    May 01, 2009 - years (based from 12/31/06) were coded as 1.0, drugs approved between 4-13 years as 0.5, and drugs … Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals … c The Drug Safety index value is coded as 1 for drugs with a black box warning, 0.5 for drugs that had … drugs that entered 4 to 13 years ago, and zero for drugs that entered more than 13 years ago and zero … the drugs shifted from the top tier).

24. Comparative Effectiveness of Preventive Pharmacological Treatments for Migraine | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/migraine-prevention/research-protocol
    November 03, 2011 - Drugs approved by the FDA for migraine prevention and off-label drugs examined in clinical trials. … Ariston Pharmaceuticals, Inc. … Elan Pharmaceuticals Eli Lilly and Company Endo Pharmaceuticals EUROHEAD GlaxoSmithKline HaEmek … King Pharmaceuticals Lotus Pharmaceutical MAP Pharmaceuticals, Inc. … Solvay Pharmaceuticals|Nektar Therapeutics Sorlandet Hospital HF St.

25. Migraine in Adults: Preventive Pharmacologic Treatments | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/migraine-prevention/research-2013
    April 18, 2013 - Studies that compared drugs with inactive controls, nonpharmacologic interventions, or other drugs were … For episodic migraine, RCTs examined 59 drugs from 14 drug classes. … All approved drugs (topiramate, divalproex, timolol, and propranolol), some off-label beta blockers, … Drugs would result in clinical improvement in 200 to 400 patients per 1,000 treated. … Evidence on improving quality of life was inconsistent across individual drugs.

26. Migraine-Adults-Executive-130408 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/migraine-adults-executive-130408.pdf
    April 01, 2013 - or approved versus off-label drugs. … Discussion All approved drugs, some off-label beta blockers, and the angiotensin inhibiting drugs were … The relative effect size of drugs was moderate: drugs would result in to 200 to 400 cases of clinical … or approved versus off-label drugs. … Modeling choice behavior for new pharmaceutical products.

27. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/juvenile-arthritis-dmards
    March 09, 2010 - Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) … Research Protocol Archived The Effectiveness of Disease-Modifying Antirheumatic Drugs … September 26, 2011 Systematic Review Archived Disease-Modifying Antirheumatic Drugs

28. #14 SUBSTANCE ABUSE (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/substanceabuse_hi_impact.pdf
    January 01, 2012 - Coordinating Council for Comparative Effectiveness Research, AHRQ is interested in innovations in drugs … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the … Prescription drugs: abuse and addiction. [internet]. … Titan Pharmaceuticals provides probuphine update after meeting with U.S.

29. Effective Health Care (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0128_07-01-2009.pdf
    January 01, 2009 - Results of Topic Selection Process & Next Steps  Generic versus brand name antiepileptic drugs … come out against the substitution of „A‟ rated generics, and neurologists use a large amount of brand drugs … In addition, many states include these drugs in their narrow therapeutic index laws. … : All patients with seizures stratified by seizure type Intervention(s): Brand name antiepileptic drugs … Comparator(s): Generic antiepileptic drugs Outcome(s): Seizure control, emergency department visits

30. Joint Disorders | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/health-topics/joint-disorders
    April 03, 2014 - Protocol Archived June 16, 2016 The Effectiveness of Disease-Modifying Antirheumatic Drugs … – An Update Research Protocol May 24, 2017 Disease-Modifying Antirheumatic Drugs

31. Obesity (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/obesity_hi_impact.pdf
    April 17, 2012 - Antiobesity Drugs for Treatment of Obesity  Key Facts: Three drugs are in phase III development for … In December 2010, Arena Pharmaceuticals announced a plan to resubmit the lorcaserin NDA by the end … Arena Pharmaceuticals. Lorcaserin hydrochloride. Drugs Future 2007;32(9):766-70. 12. … Meta-analyses of phase 3 trials show obese and overweight patients taking Arena Pharmaceuticals' … Istanbul: Arena Pharmaceuticals, Inc.; 2011 May 26 [accessed 2011 Nov 16]. [3 p].

32. Medicare Prescription Drug Data Development: Methods for Improving Patient Safety and Pharmacovigilance Using Observational Data | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/patient-safety-databases-prescriptions/research
    August 26, 2008 - Key words: adverse drug events, Alzheimer's disease, dementia, drug safety, methodology, pharmaceuticals … Introduction Background for This Study Pharmaceuticals, like all health care interventions, offer … Dementia, Pharmaceuticals, and Adverse Drug Events Dementia, including Alzheimer's disease, is one … Of particular interest initially are the benefits and risks of pharmaceuticals. … Conclusions Methodological Approach Defining conditions and pharmaceuticals .

33. Effective Health Care (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0289_03-10-2008.pdf
    January 01, 2008 -  Treatment of epilepsy, which encompasses the comparative effectiveness of newer antiepileptic drugs …  The topic of generic versus brand name antiepileptic drugs could also be considered for a potential … effectiveness of treatments for epilepsy in children (in particular new versus older antiepileptic drugs … is outdated and does not include new trial data, such as the SANAD (Standard and New Antiepileptic Drugs … Regarding the question of generic versus brand name antiepileptic drugs, the feasibility of a full review

34. Disposition of Comments for Migraine in Adults: Preventive Pharmacologic Treatments (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/migraine-prevention_disposition-comments.pdf
    April 18, 2013 - We did review off-label drugs available in the US. … of the outcomes with different drugs. … The large number of off label drugs may reflects the fact that approved drugs have undesirable balance … drugs from different classes. … , as well as individual drugs.

35. Communicating Harms and Benefits of Prescription Drugs to Healthcare Consumers (ppt file)
    effectivehealthcare.ahrq.gov/sites/default/files/communicating_risk_hickam.ppt
    December 01, 2006 - Communicating Harms and Benefits of Prescription Drugs to Healthcare Consumers Communicating Harms … and Benefits of Prescription Drugs to Healthcare Consumers John M. … Center Agency for Healthcare Research and Quality Effective Health Care Program 1.bin Themes Drugs

36. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis – An Update to the 2006 Report | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/osteoarthritis-pain/research-protocol
    August 05, 2010 - Patients with osteoarthritis also use over-the-counter supplements not regulated by the FDA as pharmaceuticals … In addition, efficacy and safety may vary for individual drugs within a class. … Pharmacokinetics, Indications, and Dosing of Drugs to be Included. … Non-steroidal anti-inflammatory drugs. … Non-steroidal anti-inflammatory drugs for low-back pain.

37. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/juvenile-arthritis-dmards/research
    September 26, 2011 - 2012 Disposition of Comments Report Jul. 3, 2013 Surveillance Report Disease-Modifying Antirheumatic Drugs … Structured Abstract Objectives To summarize the benefits and harms of disease-modifying antirheumatic drugs … (DMARDs) compared to conventional treatment (non-steroidal anti-inflammatory drugs [NSAIDs] and/or intra-articular … DMARDs across categories of JIA, and registries are needed to better understand the risks of these drugs

38. Communicating Harms and Benefits of Prescription Drugs to Health Care Consumers (Eisenberg Center Conference Series 2006) | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/eccs-2006
    September 30, 2006 - Communicating Harms and Benefits of Prescription Drugs to Health Care Consumers (Eisenberg Center Conference … September 30, 2006 White Paper Communicating Harms and Benefits of Prescription Drugs

39. Treatments for Seasonal Allergic Rhinitis | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/allergy-seasonal/research
    July 16, 2013 - We sought to compare the following classes of drugs: oral and nasal antihistamines and decongestants; … Inclusion was limited to studies that reported an outcome of interest and directly compared drugs of … Across all comparisons, 20 of 39 drugs FDA approved for the treatment of SAR were studied. … Conclusions were limited by (1) lack of comparative evidence for all drugs within each class and (2)

40. S96 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/s96.pdf
    October 01, 2007 - Of 10,383 reports in 2004, 100% listed patient age, sex, and disposition; 98% listed the implicated drugs … provides detailed and timely infor- mation on outpatient ADEs treated in EDs and identifies specific drugs … Deiden- tified data are then forwarded to CDC where all case reports involving pharmaceutical products … drugs are suspected, this information may be added as a free-text description. … Risk assessment of drugs, biologics and therapeutic devices: present and future issues.